RESUMEN
PURPOSE: To characterize the gadopentetate dimeglumine-enhanced MR features of recurrent medulloblastoma. METHODS: The postsurgical gadopentetate dimeglumine-enhanced MR images of 48 patients (206 head examinations) with prior resection of medulloblastoma were retrospectively evaluated for enhancement in the brain parenchyma, meninges (dura, pia-arachnoid), and ventricles. RESULTS: Nineteen patients had recurrent tumor as determined by clinical course and positive imaging studies. Seventeen patients with recurrent disease had intracranial enhancement predominating in the pia-arachnoid (63%) or as a focal nodular brain lesion (26%). Three of these patients also had intraventricular metastases. None of the clinically healthy patients had these findings. One patient had recurrent tumor presenting within the fourth ventricle. Only 3 of 8 intraventricular lesions observed in the 4 patients initially enhanced with gadopentetate dimeglumine. Another patient with recurrent disease had extensive skeletal metastases without involvement of the central nervous system. Dural enhancement was observed in patients both with (42%) and without (38%) recurrent tumor. CONCLUSION: The MR findings of pia-arachnoidal or focal nodular brain enhancement are highly specific in the diagnosis of recurrent medulloblastoma. Pia-arachnoidal or focal brain enhancement were also the most frequent patterns associated with recurrent tumor. Dural enhancement alone is not a reliable indicator of recurrent medulloblastoma. Not all intraventricular metastases enhance with gadopentetate dimeglumine, and careful evaluation for nonenhancing lesions within the ventricles should be made on postoperative MR examinations.
Asunto(s)
Neoplasias Encefálicas/diagnóstico , Medios de Contraste , Gadolinio , Imagen por Resonancia Magnética/métodos , Meduloblastoma/diagnóstico , Meglumina , Recurrencia Local de Neoplasia/diagnóstico , Compuestos Organometálicos , Ácido Pentético/análogos & derivados , Adolescente , Adulto , Aracnoides/patología , Neoplasias Óseas/secundario , Encéfalo/patología , Neoplasias Encefálicas/cirugía , Ventrículos Cerebrales/patología , Niño , Preescolar , Combinación de Medicamentos , Duramadre/patología , Femenino , Estudios de Seguimiento , Gadolinio DTPA , Humanos , Aumento de la Imagen/métodos , Lactante , Masculino , Meduloblastoma/secundario , Meduloblastoma/cirugía , Recurrencia Local de Neoplasia/cirugía , Piamadre/patología , Cuidados Posoperatorios , Estudios RetrospectivosRESUMEN
PURPOSE: To determine the incidence, appearance, and clinical significance of lesions mimicking intraparenchymal hemorrhages on CT in patients treated with intracranial intraarterial thrombolysis for acute strokes. METHODS: Ten cases of acute stroke treated with direct intraarterial urokinase infusion were retrospectively reviewed. Clinical and radiographic findings before and after therapy were all evaluated. RESULTS: Six (60%) of the 10 patients showed areas of increased attenuation on CT shortly after thrombolytic therapy. The lesions were associated with clinical deterioration in two cases (20%); in these two cases the lesions persisted on CT for several days. The lesions were asymptomatic in two (20%) cases; the lesions cleared on CT within 24 hours in those two patients. In two (20%) patients, immediate clinical improvement was evident despite the radiodense areas. These lesions also cleared within 24 hours. CT Hounsfield unit measurements of four of the lesions revealed very high Hounsfield units in two lesions, only one of which was a symptomatic lesion. MR in two cases revealed residue of hemorrhage. CONCLUSION: Intraparenchymal areas of increased attenuation may be seen on the CT scans of patients after intraarterial thrombolysis. The density is often at least partially attributable to contrast extravasation. The lesions should not necessarily be interpreted as hemorrhage alone, especially in the absence of clinical deterioration. Rapid clearing may be a positive prognostic sign.
Asunto(s)
Hemorragia Cerebral/diagnóstico por imagen , Trastornos Cerebrovasculares/tratamiento farmacológico , Terapia Trombolítica , Tomografía Computarizada por Rayos X , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Enfermedad Aguda , Adulto , Anciano , Encéfalo/irrigación sanguínea , Hemorragia Cerebral/etiología , Trastornos Cerebrovasculares/diagnóstico por imagen , Femenino , Humanos , Infusiones Intraarteriales , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Terapia Trombolítica/efectos adversos , Activador de Plasminógeno de Tipo Uroquinasa/uso terapéuticoRESUMEN
BACKGROUND AND PURPOSE: Postoperative MR imaging is routinely performed for staging of medulloblastoma because of frequent tumor dissemination along CSF pathways. The goals of this study were to: 1) determine the timing of disease occurrence and contrast-enhanced MR imaging features of disseminated medulloblastoma involving the spine and their relationship to patient outcomes; and 2) compare the diagnostic accuracy of MR imaging findings with CSF cytologic analysis. METHODS: Medical records, pathologic reports, and unenhanced and contrast-enhanced postoperative MR images of the spine and head from 112 patients who had resection of medulloblastoma were retrospectively reviewed. MR images of the spine were evaluated for abnormal contrast enhancement in the meninges and vertebral bone marrow. MR images of the head were evaluated for recurrent or residual intracranial tumor. Imaging data were correlated with available CSF cytologic results and patient outcomes. RESULTS: Twelve patients (11%) had tumor within the spinal leptomeninges depicted on MR images at the time of diagnosis. Twenty-five patients (22%) had disseminated disease in the spine (leptomeninges, n = 22; vertebral marrow, n = 1; or both locations, n = 2) on MR images 2 months to 5.5 years (mean, 2 years) after initial surgery and earlier negative imaging examinations. Eleven other patients (10%) had recurrent intracranial medulloblastoma without spinal involvement seen with MR imaging. Spinal MR imaging had a sensitivity of 83% in the detection of disseminated tumor, whereas contemporaneous CSF cytologic analysis had a sensitivity of 60%. The sensitivity of CSF cytologic analysis increased to 78% with acquisition of multiple subsequent samples, although diagnosis would have been delayed by more than 6 months compared with diagnosis by spinal MR imaging in six patients. Spinal MR imaging was found to have greater overall diagnostic accuracy than CSF cytologic analysis in the early detection of disseminated tumor (P = .03). Spinal MR imaging confirmed disseminated tumor when contemporaneous CSF cytologic findings were negative in 13 patients, whereas the opposite situation occurred in only two patients. False-positive results for spinal MR imaging and CSF cytologic analysis occurred when these examinations were obtained earlier than 2 weeks after surgery. The 5-year survival probability for patients with spinal tumor was 0.24 +/- 0.08 versus 0.68 +/- 0.05 for the entire study group. CONCLUSION: Spinal MR imaging was found to have greater diagnostic accuracy than CSF cytologic analysis in the early detection of disseminated medulloblastoma. CSF cytologic analysis infrequently confirmed disseminated tumor when spinal MR imaging results were negative. Delaying spinal MR imaging and CSF cytologic analysis by more than 2 weeks after surgery can reduce false-positive results for both methods. The presence of disseminated medulloblastoma in the spine seen with MR imaging is associated with a poor prognosis.
Asunto(s)
Neoplasias Cerebelosas/patología , Meduloblastoma/patología , Neoplasias de la Médula Espinal/diagnóstico , Neoplasias de la Médula Espinal/secundario , Neoplasias de la Columna Vertebral/diagnóstico , Neoplasias de la Columna Vertebral/secundario , Adolescente , Adulto , Anciano , Neoplasias de la Médula Ósea/diagnóstico , Neoplasias de la Médula Ósea/secundario , Neoplasias Óseas/secundario , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Meduloblastoma/mortalidad , Meduloblastoma/cirugía , Persona de Mediana Edad , Neoplasias de la Médula Espinal/mortalidad , Neoplasias de la Columna Vertebral/mortalidad , Tasa de SupervivenciaAsunto(s)
Proteínas de Homeodominio/genética , Leucemia Mieloide Aguda/genética , Proteína de la Leucemia Mieloide-Linfoide/genética , Factores de Transcripción/genética , Secuencia de Bases , Cartilla de ADN , N-Metiltransferasa de Histona-Lisina , Humanos , Lactante , Cariotipificación , Reacción en Cadena de la PolimerasaRESUMEN
PURPOSE: A preliminary evaluation of the efficacy and safety of treating patients with acute stroke with intraarterial urokinase infusions was performed. PATIENTS AND METHODS: Twelve patients with acute stroke were treated within 8 hours of symptom onset (average, 5 hours). Thrombolysis was performed within the middle cerebral (n = 10), internal carotid (n = 1), and basilar (n = 1) arteries. Urokinase (160,000-500,000 IU) was infused through microcatheters placed into or adjacent to the thrombi. RESULTS: Thrombolysis was angiographically successful in nine patients (75%), all of whom had long-term neurologic improvement. No or minimal neurologic deficits were present in six patients (50%). Thrombolysis failed in three patients (25%); one patient died and two developed severe permanent neurologic deficits. No hemorrhagic complications occurred. CONCLUSION: Preliminary results suggest that intraarterial urokinase infusion may be effective and safe for treating patients with acute stroke. Potentially devastating neurologic damage was averted or lessened in nine patients (75%). No additional neurologic damage was caused by intervention in the remaining three patients (25%).